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INTRODUCTION
Ischemic stroke shares common risk factors with coronary ar-
tery occlusive disease (CAOD). Myocardial infarction is one of 
the leading causes of death during long-term follow-up in pa-
tients with an ischemic stroke.1-4 CAOD was present in about 
70% and significant (≥50%) stenosis was noted in about 30% 
of stroke patients without a history of CAOD in studies using 
autopsy or coronary catheter angiography.5,6 However, evalua-
tion of asymptomatic CAOD in stroke patients is not commonly 
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undertaken in routine clinical practice.
Recently, multi-detector coronary computed tomography 
(MDCT) has been introduced for evaluating coronary arteries. 
MDCT accurately detects the presence of CAOD,7 and is a con-
venient and safe test. MDCT-based coronary findings have 
been found to be strong predictors of future cardiovascular 
events or death in patients with or without known CAOD.8-10 
Previous studies using MDCT showed that CAOD was present 
in 48–70% and significant CAOD was present in 18–33% of isch-
emic stroke patients without a previous history of CAOD.11,12 
MDCT has additional benefits in stroke patients, as it can de-
tect the potential cardiac or aortic sources of embolism.13
Diagnosis of asymptomatic CAOD and hidden cardiac or 
aortic causes of stroke in stroke patients may help to reduce 
the risks of cardiovascular events and recurrent strokes. How-
ever, it remains unknown whether evaluation using MDCT in 
stroke patients affects long-term outcomes. Therefore, we in-
vestigated whether long-term cardio-cerebrovascular out-
comes differ between patients who underwent MDCT during 
the acute stage of stroke and those who did not.
MATERIALS AND METHODS
Study design and population
This was a retrospective study of a prospective cohort of isch-
emic stroke patients designed to evaluate the usefulness of 
MDCT. This cohort included consecutive patients with acute 
cerebral infarction or transient ischemic attack within 7 days 
after symptom onset who were admitted to the neurology de-
partment of the Severance Stroke Center, Yonsei University in 
Seoul, Korea. Upon admission, all patients were thoroughly 
evaluated to determine demographic data, medical history, 
clinical manifestations, and vascular risk factors.14 All patients 
underwent brain CT and/or magnetic resonance imaging with 
cerebral angiographic studies, standard blood tests, and 12-
lead electrocardiography. Most patients were admitted to a 
stroke unit and were monitored continuously with electrocar-
diography during their stay (average 4.9 days). Holter monitor-
ing was also performed if a cardiac embolism was suspected on 
the basis of infarction pattern, patient age, or previous cardiac 
history. Transesophageal echocardiography was a part of the 
routine examination, unless it could not be performed due to ei-
ther the patient’s condition or failure to obtain informed consent.
For determination of the presence of asymptomatic CAOD 
in stroke patients, since July 2006, MDCT was consecutively 
performed when a patient had at least one of the following: 1) 
presence of atherosclerosis in an intracranial or extracranial 
cerebral artery; 2) presence of ≥2 risk factors for CAOD, such as 
hypertension, diabetes mellitus, dyslipidemia, cigarette smok-
ing, and central obesity; and 3) old age (males >45 years, fe-
males >55 years).12 MDCT was not performed if patients had 
1) known CAOD; 2) high pulse rates that were not controlled 
with beta-blockers at the time of MDCT; 3) poor cooperation; 
4) impaired renal function; or 5) failure to obtain informed 
consent. When significant (≥50%) stenosis of the coronary ar-
tery was observed on MDCT, the patients were routinely re-
ferred to cardiologists at our cardiovascular center. CAOD was 
then managed at the discretion of the cardiologists and neurol-
ogists, which included percutaneous coronary intervention 
with stent (PCI) and coronary artery bypass graft (CABG). This 
study was approved by the Institutional Review Board of Sev-
erance Hospital, Yonsei University Health System. Informed 
consent was waived due to the retrospective nature of the study. 
Clinical variables
We collected data on vascular risk factors for coronary heart 
disease, such as hypertension, diabetes mellitus, hyperlipid-
emia, and current smoking. The presence of valvular heart dis-
ease, atrial fibrillation, congestive heart failure, previous ischemic 
or hemorrhagic stroke, peripheral arterial occlusive diseases, 
metabolic syndrome, underlying malignancy (cancer diagnosed 
within 6 months prior to the index stroke, ongoing treatment 
for cancer, or recurrent or metastatic cancer), chronic kidney 
disease (estimated glomerular filtration rate < 30 mL/min/ 
1.73 m2), and prior medication before the index stroke were 
also investigated. Initial stroke severity was determined based 
on the National Institute of Health Stroke Scale (NIHSS). Ce-
rebral atherosclerosis was defined as having at least ≥1 steno-
occlusive lesion of >50% based on the North American Symp-
tomatic Carotid Endarterectomy Trial (for extracranial arteries)15 
or on the Warfarin vs. Aspirin for Symptomatic Intracranial 
Disease method (for intracranial arteries).16 Framingham risk 
scores were calculated for each patient. Data on lipid profiles 
were also obtained.
Outcome data
Outcomes measured in this study were death and first occur-
rence of cardiovascular events or recurrent ischemic stroke. We 
obtained data for vascular events and death (date and causes 
of death) by review of the medical records and face-to-face or 
telephone interviews carried out by the stroke research nurse 
and stroke specialists. For mortality data, the date and cause 
of death were also identified using data from the Korean Na-
tional Statistical Office. These mortality data are known to be 
reliable because they are collected based on a unique 13-digit 
identification code assigned to subjects at birth and on the 
death certificate. The causes of death are coded according to the 
International Classification of Disease, 10th Revision (ICD-10). 
Cardiovascular events were defined as nonfatal or fatal myo-
cardial infarction (ICD-10 code I20-21), chronic ischemic heart 
disease (I25), sudden cardiac death (R96), death due to ven-
tricular fibrillation (I49), or congestive heart failure (I50). The 
ICD-10 code used for coding fatal or nonfatal ischemic stroke 
was I63. The date of censoring was December 31, 2012. 
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Statistical analysis
Continuous variables are expressed as mean±standard devia-
tion, and categorical data are expressed as number (percent-
age). The chi-square test or Student’s t-test was used to com-
pare groups for categorical variables and continuous data, as 
appropriate. A Kaplan-Meier estimate of survival was used to 
compare the differences in rates of cardiovascular events or re-
current ischemic stroke between the MDCT (+) group and the 
MDCT (-) group. Differences were determined by the log-rank 
test. To identify independent factors for the events, multiple Cox 
regression analysis was used.
Further, to reduce the potential effects of selection bias and 
confounding factors in this retrospective cohort study, we es-
timated propensity scores for each of the entire patients en-
rolled in this study to match the patients who had undergone 
MDCT to those who had not. This was computed for each pa-
tient with a logistic regression model, including variables of 
age, sex, hypertension, diabetes, hypercholesterolemia, current 
smoking status, valvular heart diseases, atrial fibrillation, con-
gestive heart failure, previous ischemic or hemorrhagic stroke, 
peripheral arterial occlusive diseases, metabolic syndrome, 
underlying malignancy, chronic kidney disease, prior antiplate-
let/anticoagulant/statin use, initial stroke severity, concomitant 
cerebral atherosclerosis, and lipid profiles. Each patient was 
then assigned an estimated propensity score, which was the 
predicted probability of undergoing MDCT on the basis of pa-
tient’s observed baseline characteristics. Then, we divided the 
cohort into five strata defined by quintiles of estimated propen-
sity scores. Cox proportional hazards models were employed 
separately within each stratum to compare the overall survival 
of patients undergoing MDCT with that of patients not under-
going MDCT. The five hazard ratios (HR) estimated from each 
stratum were combined into an overall HR for the whole cohort.
We also used Cox models for adjusting differences between 
the groups in other ways. First, regression adjustment was per-
formed with inclusion of the propensity score as a linear pre-
dictor in the model. Second, the inverse probability of treat-
ment weighting was used. We used Cox regression analysis to 
adjust the inverse probability of treatment weighting, as well 
as baseline characteristics. Finally, propensity score matching 
was conducted between paired patients who underwent MDCT 
and those who did not undergo MDCT. After matching, the 
baseline characteristics were compared with McNemar’s test 
and the paired t-test. Clustered Cox regression analysis was 
also performed. All calculated p-values were two-sided, and 
p<0.05 was considered to be statistically significant. Statistical 
analyses were performed using the Windows IBM SPSS soft-
ware package (version 20, IBM Corp., Armonk, NY, USA) and 
SAS (version 9.2, SAS Inc., Cary, NC, USA).
RESULTS
Study population
A total of 4381 consecutive patients were registered between 
July 2006 and December 2012. This comparative analysis was 
designed to investigate the usefulness of MDCT among pa-
tients who had no previous history of CAOD. Consequently, 
of the 4381 patients, we first excluded 938 patients who had a 
history of CAOD (myocardial infarction, angiographically con-
firmed CAOD, unstable angina, PCI, or CABG) or who under-
went coronary angiographic evaluation within 1 year prior to 
the index stroke. We further excluded 160 patients who did not 
have any of the inclusion criteria for screening of asymptom-
atic CAOD with MDCT. Patients with unavailable data on ini-
tial NIHSS scores (n=19), estimated glomerular filtration rate 
(n=20), or incomplete lipid profiles (n=100) and those who died 
of acute index stroke within 7 days of symptom onset (n=27) 
were also excluded. Finally, 3117 patients were included in this 
study. Among them, 1842 patients underwent MDCT and 1275 
patients did not undergo MDCT (Fig. 1). In the MDCT (-) group 
(n=1275), the reasons for not performing MDCT could be de-
termined as follows: medical reasons (52.5%, 669/1275), such 
as poor cooperation or general condition (34.0%), renal or con-
trast agent-related factors (10.0%), and rapid heart rate (8.5%); 
and nonmedical reasons (47.5%, 606/1275), including a failure 
to obtain informed consent or no specific documented reasons.
Fig. 1. Patient selection for this study. TIA, transient ischemic attack; CAOD, 
coronary artery occlusive disease; MDCT, multi-detector coronary com-
puted tomography.
All ischemic stroke or TIA patients admitted between 
July 2006 and December 2012 (n=4381)
Total study population (n=3117)
MDCT (+) (n=1842) MDCT (-) (n=1275)
Patients with known CAOD and those who had already 
received CAOD evaluation (n=938)
Patients who did not meet the criteria for MDCT (n=160)
Patients with incomplete data (n=139)
Patients who died within 7 days after  
index stroke presentation (n=27)
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Baseline characteristics of the MDCT (+) and MDCT 
(-) groups
The mean age of the 3117 ischemic stroke patients enrolled in 
this study was 65.7±12.0 years, and 60.5% of patients were men 
(n=1886). On the basis of Framingham risk scores, 28.6% of 
patients were classified into a low risk group (10-year risk <10%), 
33.2% into a moderate risk group (10–20%), and 38.2% into a 
high risk group (>20%). In the MDCT (+) group (1842 patients), 
asymptomatic CAOD was detected in 1237 patients (67.2%): 
minimal CAOD in 725 (39.4%), 1-vessel disease in 301 (16.3%), 
2-vessel disease in 149 (8.1%), and 3-vessel disease in 62 (3.4%).
Compared to patients of the MDCT (+) group, those of the 
MDCT (-) group were more likely to be older, female, and non-
smokers and to have hypertension, valvular heart disease, atrial 
fibrillation, congestive heart failure, previous ischemic stroke, 
peripheral arterial occlusive diseases, underlying malignancy, 
chronic kidney disease, prior anticoagulant treatment, more 
severe stroke, concomitant cerebral atherosclerosis, and rela-
tively low triglyceride, low density lipoprotein, or high density 
lipoprotein levels (Table 1). In terms of medication at discharge, 
statins were more frequently prescribed in the MDCT (+) 
group (n=1773, 96.3%) than in the MDCT (-) group (n=1148, 
90.0%) (p<0.001). There were similar trends in prescribing an-
tithrombotics [n=1810 (98.3%) in MDCT (+) vs. n=1202 (94.3%) 
in MDCT (-), p<0.001] or beta-blockers [n=631 (34.3%) in 
MDCT (+) vs. n=287 (22.5%) in MDCT (-), p<0.001].
Cardiovascular and cerebrovascular outcomes
Outcomes in the original population
During a follow-up of 38.0±24.8 months (range: 0–85.9 months), 
486 patients (15.6%) died. Recurrent stroke developed in 297 
patients (9.5%) [fatal stroke in 106 (3.4%) and nonfatal stroke 
in 191 (6.1%)] and cardiovascular events in 60 patients (1.9%) 
[fatal myocardial infarction or sudden cardiac death in 27 
(0.9%), nonfatal myocardial infarction in 29 (0.9%), and con-
Table 1. Comparison of Baseline Characteristics between the MDCT (+) and MDCT (-) Groups
Variable
Before matching (n=3117) After matching (n=1616)
MDCT (+) 
(n=1842)
MDCT (-) 
(n=1275)
p value
MDCT (+) 
(n=808)
MDCT (-) 
(n=808)
p value
Age 64.0±11.1 68.1±12.8 <0.001 65.0±11.3 65.8±12.9 0.109
Male sex 1176 (63.8) 710 (55.7) <0.001 483 (59.8) 479 (59.3) 0.872
Hypertension 1350 (73.3) 1000 (78.4) 0.001 620 (76.7) 623 (77.1) 0.903
Diabetes 565 (30.7) 430 (33.7) 0.072 254 (31.4) 265 (32.8) 0.586
Hypercholesterolemia 174 (9.4) 98 (7.7) 0.087 67 (8.3) 68 (8.4) >0.999
Current smoker 505 (27.4) 237 (18.6) <0.001 192 (23.8) 179 (22.2) 0.449
Valvular heart disease 66 (3.6) 88 (6.9) <0.001 38 (4.7) 42 (5.2) 0.724
Atrial fibrillation 245 (13.3) 375 (29.4) <0.001 155 (19.2) 148 (18.3) 0.664
Congestive heart failure 34 (1.8) 70 (5.5) <0.001 17 (2.1) 18 (2.2) >0.999
Previous ischemic stroke 235 (12.8) 246 (19.3) <0.001 110 (13.6) 128 (15.8) 0.217
Previous intracranial hemorrhage 59 (3.2) 47 (3.7) 0.464 25 (3.1) 24 (3.0) >0.999
Peripheral arterial occlusive disease 88 (4.8) 83 (6.5) 0.037 34 (4.2) 45 (5.6) 0.235
Metabolic syndrome 741 (40.2) 481 (37.7) 0.159 295 (36.5) 310 (38.4) 0.477
Malignancy 181 (9.8) 157 (12.3) 0.028 94 (11.6) 95 (11.8) >0.999
Chronic kidney disease 29 (1.6) 78 (6.1) <0.001 18 (2.2) 13 (1.6) 0.442
Prior medication
Antiplatelet 535 (29.0) 375 (29.4) 0.825 223 (27.6) 229 (28.3) 0.786
Anticoagulant 71 (3.9) 114 (8.9) <0.001 49 (6.1) 45 (5.6) 0.738
Statin 253 (13.7) 192 (15.1) 0.299 115 (14.2) 117 (14.5) 0.944
Initial NIHSS <0.001 0.212
0–5 1478 (80.2) 704 (55.2) 576 (71.3) 585 (72.4)
6–19 350 (19.0) 440 (34.5) 221 (27.4) 216 (26.7)
≥20 14 (0.8) 131 (10.3) 11 (1.4) 7 (0.9)
Concomitant cerebral atherosclerosis 1011 (54.9) 846 (66.4) <0.001 470 (58.2) 486 (60.1) 0.424
Total cholesterol >6.2 mmol/L 154 (8.4) 99 (7.8) 0.549 67 (8.3) 68 (8.4) >0.999
Triglyceride >3.9 mmol/L 467 (25.4) 266 (20.9) 0.004 186 (23.0) 183 (22.6) 0.907
High density lipoprotein <1.3 mmol/L 1435 (77.9) 926 (72.6) 0.001 611 (75.6) 612 (75.7) >0.999
Low density lipoprotein >2.6 mmol/L 1121 (60.9) 723 (56.7) 0.02 471 (58.3) 472 (58.4) >0.999
MDCT, multi-detector coronary computed tomography; NIHSS, National Institutes of Health Stroke Scale.
Values are represented as numbers (%) or mean±SD.
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gestive heart failure in 4 (0.1%)]. The frequency of receiving re-
vascularization therapy was statistically different between the 
two groups (p<0.001) in that 96 patients (5.2%) received PCI 
(n=87) or CABG (n=9) in the MDCT (+) group, while 13 patients 
(1.0%) received PCI (n=9) or CABG (n=4) in the MDCT (-) 
group, during follow-up. The occurrence of cardiovascular 
events was not associated with the Framingham risk score 
stratification (p=0.400).
Compared to patients in the MDCT (+) group, those in the 
MDCT (-) more frequently experienced death (27.9% vs. 7.1%, 
p<0.001), cardiovascular events (3.5% vs. 0.8%, p<0.001), and 
recurrent stroke (13.3% vs. 6.9%, p<0.001). Kaplan-Meier curves 
showed that the MDCT (-) group had higher risks of death, 
cardiovascular events, and recurrent ischemic stroke than the 
MDCT (+) group (Fig. 2). The mean annual risk of death, car-
diovascular events, or recurrent ischemic stroke was higher in 
the MDCT (-) group than in the MDCT (+) group (9.34% vs. 
2.47% for death, 1.20% vs. 0.29% for cardiovascular events, 
and 4.70% vs. 2.56% for recurrent ischemic stroke). After ad-
justing for all demographic and clinical characteristics in mul-
tivariate Cox proportional hazard models, there were signifi-
cantly higher risks of death, cardiovascular events, and recurrent 
stroke in the MDCT (-) group than in the MDCT (+) group 
(Table 2).
Outcomes in the propensity score-matched population
Propensity score matching resulted in well-balanced match-
ing between the MDCT (+) group and the MDCT (-) group. All 
characteristics of the two groups were well balanced with 
those of the unmatched cohort (Table 1). The baseline charac-
teristics in the five strata adjusted for propensity scores are 
shown in Supplementary Table 1 (only online).
Kaplan-Meier curves showed that the MDCT (-) group was 
in higher risk of death and cardiovascular events (Fig. 3). All of 
the five propensity score-adjusted models consistently dem-
onstrated that the MDCT (-) group was at a higher risk of death 
and cardiovascular events (Table 2). In stratified analysis 
based on the propensity score, the difference in the risk of death 
and cardiovascular events between the MDCT (-) group and 
the MDCT (+) group was remarkably significant among pa-
tients with high propensity scores. The MDCT (-) group seemed 
to also have a higher risk of recurrent stroke in most propensi-
ty score-adjusted models than did the MDCT (+) group. How-
ever, the increased risk of recurrent stroke was weaker than that 
of cardiovascular events. For example, in the MDCT (-) group, 
the HR for cardiovascular events in stratified analyses based 
on propensity scores was 2.692 [confidence interval (CI) 1.450–
4.997, p=0.002], while that for recurrent stroke was 1.419 (95% 
CI 1.108–1.816, p=0.005) (Table 2). The results of 1:1 propensity 
matching analysis showed the MDCT (-) was related with death 
(HR 2.783, 95% CI 1.987–3.897, p<0.001) or cardiovascular 
events (HR 3.2, 95% CI 1.172–8.735, p=0.023), but not with the 
recurrent stroke (HR 1.173, 95% CI 0.810–1.698, p=0.398).
In addition, we performed comparative analyses using the 
data of the MDCT (+) group (n=1842) and 606 patients of MDCT 
(-) subgroup who had not undergone MDCT due to nonmed-
ical reasons (Supplementary Table 2, only online). Kaplan-Mei-
er curves and Cox proportional hazards models showed pa-
tients in the MDCT (-) subgroup had significantly higher risks 
of all predetermined outcomes (Supplementary Fig. 1, Supple-
mentary Table 3, only online). Propensity score analyses 
showed that compared with the MDCT (+) group, MDCT (-) 
group was higher risk of death and tended to be higher risk of 
cardiovascular events or recurrent stroke (Supplementary Fig. 2, 
Supplementary Table 3, only online).
DISCUSSION
In this study, we found that the risks of death, cardiovascular 
events, and recurrent stroke were higher in stroke patients who 
were not evaluated using MDCT during admission than in 
those who were evaluated. However, evaluation using MDCT 
was not randomized; consequently, many baseline character-
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Fig. 2. Kaplan-Meier survival curves for (A) death (B) cardiovascular events, and (C) recurrent stroke according to the performance of MDCT in the entire 
population. MDCT, multi-detector coronary computed tomography.
Number at risk
  MDCT (+) 1842 1496 1184 875 492 263 57 0
  MDCT (-) 1275 956 778 626 451 293 144 0
Number at risk
  MDCT (+) 1842 1490 1178 867 485 259 56 0
  MDCT (-) 1275 948 768 616 440 288 142 0
Number at risk
  MDCT (+) 1842 1432 1114 813 458 237 51 0
  MDCT (-) 1275 916 733 583 413 265 120 0
0       1       2        3       4        5       6        7
MDCT (+)
MDCT (-)
MDCT (+)
MDCT (-)
MDCT (+)
MDCT (-)
p<0.001 p<0.001 p<0.001
0       1       2        3       4        5       6        7 0       1       2        3       4        5       6        7
Follow-up year Follow-up year Follow-up year
A B C
119
Young Dae Kim, et al.
https://doi.org/10.3349/ymj.2017.58.1.114
istics differed between the MDCT (+) group and the MDCT (-) 
group. Therefore, we compared outcomes in a propensity score-
matched population. Comparison using various models in 
this propensity score-matched population also showed signif-
icant differences in the risk of death, cardiovascular events, and 
recurrent stroke between two groups. In particular, the high 
Table 2. Impact of Not Performing MDCT on Hazard Ratios for Cardiovascular Events and Recurrent Stroke
Event Sample size, no. Hazard ratio (95% CI) p value
Death
Unadjusted model 1275 and 1842 4.038 (3.302–4.937) <0.001
Multivariable-adjusted model* 1275 and 1842 2.248 (1.808–2.795) <0.001
Propensity score-adjusted model†
Stratification 1275 and 1842 2.410 (1.950–2.980) <0.001
Within-propensity score quintile
1 (kowest propensity) 149 and 474 0.845 (0.170–4.214) 0.838
2 162 and 462 2.347 (1.304–4.225) 0.004
3 198 and 425 1.736 (1.092–2.760) 0.020
4 303 and 321 2.731 (1.834–4.068) <0.001
5 (high propensity) 463 and 160 2.888 (1.960–4.257) <0.001
Regression adjustment 1275 and 1842 2.307 (1.858–2.866) <0.001
Weighting (stabilized IPTW) 1275 and 1842 2.491 (2.090–2.970) <0.001
Matching 1:1 808 and 808 2.783 (1.987–3.897) <0.001
Cardiovascular events
Unadjusted model 1275 and 1842 4.476 (2.493–8.034) <0.001
Multivariable-adjusted model* 1275 and 1842 2.896 (1.551–5.408) <0.001
Propensity score-adjusted model†
Stratification 1275 and 1842 2.692 (1.450–4.997) 0.002
Within-propensity score quintile
1 (lowest propensity) 149 and 474 -‡ -
2 162 and 462 1.932 (0.431–8.662) 0.389
3 198 and 425 1.075 (0.197–5.867) 0.934
4 303 and 321 2.523 (0.777–8.195) 0.124
5 (high propensity) 463 and 160 3.740 (1.137–12.304) 0.030
Regression adjustment 1275 and 1842 2.908 (1.556–5.437) 0.001
Weighting (stabilized IPTW) 1275 and 1842 3.462 (2.024–5.921) <0.001
Matching 1:1 808 and 808 3.200 (1.172–8.735) 0.023
Recurrent stroke
Unadjusted model 1275 and 1842 1.962 (1.558–2.470) <0.001
Multivariable-adjusted model* 1275 and 1842 1.278 (0.993–1.645) 0.0527
Propensity score-adjusted model†
Stratification 1275 and 1842 1.419 (1.108–1.816) 0.005
Within-propensity score quintile
1 (lowest propensity) 149 and 474 0.528 (0.177–1.576) 0.253
2 162 and 462 1.868 (0.984–3.546) 0.056
3 198 and 425 1.248 (0.738–2.110) 0.408
4 303 and 321 1.233 (0.776–1.959) 0.375
5 (high propensity) 463 and 160 2.091 (1.227–3.565) 0.007
Regression adjustment 1275 and 1842 1.288 (1.000–1.0659) 0.050
Weighting (stabilized IPTW) 1275 and 1842 1.527 (1.235–1.889) <0.001
Matching 1:1 (paired)  808 and 808 1.173 (0.810–1.698) 0.398
MDCT, multi-detector coronary computed tomography; CI, confidence interval; IPTW, inverse probability of treatment weighting.
*This model was adjusted for age, sex, hypertension, diabetes, hypercholesterolemia, current smoking status, valvular heart diseases, atrial fibrillation, congestive 
heart failure, previous ischemic or hemorrhagic stroke, peripheral arterial occlusive diseases, metabolic syndrome, underlying malignancy, chronic kidney disease, 
prior antiplatelet/anticoagulant/statin use, initial stroke severity, and lipid profiles, †The propensity of undergoing MDCT was estimated using a multivariate logistic 
regression model, which included age, sex, hypertension, diabetes, hypercholesterolemia, current smoking status, valvular heart diseases, atrial fibrillation, conges-
tive heart failure, previous ischemic or hemorrhagic stroke, peripheral arterial occlusive diseases, metabolic syndrome, underlying malignancy, chronic kidney dis-
ease, prior antiplatelet/anticoagulant/statin use, initial stroke severity, and lipid profiles, ‡This could not be estimated because of no event in MDCT (+) group.
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strata group (the highest propensity) more frequently suffered 
from death, cardiovascular events, and recurrent strokes.
Diagnosis of asymptomatic, but significant CAOD, using 
MDCT could change a treatment strategy. Likely, physicians 
and patients might be more motivated to manage modifiable 
risk factors for cardiovascular disease and to stick to treatment 
with medication if they recognized the presence of asymp-
tomatic CAOD. When it comes to revascularization therapy, 
there has been no strong evidence of the usefulness of routine 
PCI for reducing cardiovascular events in patients with stable 
CAOD.17,18 However, because the severity of silent CAOD was 
a strong predictor of future cardiovascular events in stroke pa-
tients, despite the use of the best medical treatment based on 
guidelines1,18 and revascularization therapy, including CABG 
and PCI, may be helpful for specific group of patients, such as 
those with ≥50% stenosis of the left main coronary artery,17,19 
some patients in the MDCT (+) of our study might have bene-
fitted from revascularization therapy. 
Many of the patients who did not undergo MDCT in this study 
might have had significant CAOD that was undiagnosed on 
discharge. Indeed, about 18–33% of stroke patients have been 
reported to have asymptomatic but significant CAOD.5,6,11 In 
this study, significant CAOD was detected in 28% of patients 
who underwent MDCT. Thus, patients with significant CAOD 
that was not diagnosed before discharge might have had a 
greater risk of cardiovascular events during follow-up.
Notably, in the MDCT (-) group, the annual risk was 4.2 times 
greater for cardiovascular events and 1.8 times greater for re-
current stroke than it was in the MDCT (+) group. This suggests 
that the effects of using MDCT were greater for reducing car-
diovascular events than for reducing recurrent stroke. MDCT 
is also useful in diagnosing the causes of stroke, such as aortic 
plaques, intracardiac thrombi, and patent foramen ovale. Al-
though the exact diagnosis of stroke mechanisms is helpful for 
better stroke prevention,20 many of the etiologies, which were 
detected on MDCT, might have been also detected by echo-
cardiographic studies that were a part of standard stroke eval-
uation in our center.21,22 As a result, the treatment strategy for 
the secondary prevention of stroke might have not been changed 
in most cases of our population even though cardiac or aortic 
causes of stroke were detected by MDCT. However, asymp-
tomatic CAOD could not have been diagnosed if patients were 
not evaluated using MDCT. These might be partly responsible 
for the different risks for cardiovascular events and recurrent 
stroke in the MDCT (-) group in the present study.
The present study does not address which patients are ap-
propriate candidates for coronary evaluation. However, a scien-
tific statement by the American Heart Association/American 
Stroke Association in 2003 recommended routine noninvasive 
testing for coronary heart disease in high risk groups, includ-
ing stroke patients with cerebral atherosclerosis or a Framing-
ham risk score of ≥20%.23 Previous MDCT-based studies sug-
gest that asymptomatic CAOD is common in stroke patients 
with multiple vascular risk factors and atherosclerosis of the 
cervicocephalic arteries.11,12 The present study provides sup-
portive evidence for the necessity of coronary evaluation in 
acute stroke patients. MDCT has some drawbacks, such as con-
trast agent-related side effects, radiation-related adverse ef-
fects, and the need for the patient’s cooperation to hold their 
breath for a while. However, this test has an advantage for stroke 
patients. In contrast to a treadmill test, MDCT can be performed 
in patients with the level of disability seen in many stroke pa-
tients.7 In addition, many cardiac and aortic causes of stroke 
can be diagnosed by MDCT, as described above. Therefore, 
this test can be useful especially in patients for whom trans-
esophageal echocardiography cannot be performed.13,24 De-
fining high-risk patients for future cardiovascular events that 
could benefit from cardiac evaluation using MDCT is required.
This study has merit in that it was performed in a large sam-
ple of stroke patients with a long-term follow-up. However, this 
study also has several limitations. First, evaluation using MDCT 
was not randomized. Although a previous report showed that 
asymptomatic CAOD is common regardless of the stroke 
mechanism6 and we balanced the baseline characteristics of 
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Fig. 3. Kaplan-Meier survival curves for (A) death (B) cardiovascular events, and (C) recurrent stroke according to the performance of MDCT in the propensity 
score-matched population. MDCT, multi-detector coronary computed tomography.
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patients using various propensity score matching models, there 
might still be other confounders of outcomes, such as socio-
economic status. Second, adherence to medication during fol-
low-up was not thoroughly checked. Third, although all cardi-
ologists managed patients with CAOD based on the same 
guidelines, management, including revascularization therapy, 
was not controlled. Fourth, this study was performed in a single 
university hospital in one Asian country. However, the pres-
ence of vascular risk factors and occurrence of vascular events 
(cardiovascular or cerebrovascular) can differ between differ-
ent ethnicities.25 Therefore, these limitations should be con-
sidered in the interpretation of the results of the present study.
The present study showed that stroke patients who were not 
evaluated using MDCT during admission had increased risks 
of future death, cardiovascular events, or recurrent stroke. 
However, the overall cardiovascular events were lower in this 
study population. Therefore, further studies focusing on the 
selection of high-risk patients for future cardiovascular events 
or randomized clinical trials are needed to clearly demonstrate 
the clinical usefulness of MDCT.
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